ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumor
In brief
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.
Key facts
- Study ID
- NCT06597721
- Run by
- Adcendo ApS
- People needed
- 210
- Starts
- 2024-11-25
- Expected to finish
- 2027-06-30
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Highlands Oncology Group — Rogers, Arkansas, United States (enrolling)
- Yale University Cancer Center — New Haven, Connecticut, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- START San Antonio — San Antonio, Texas, United States (enrolling)
- Macquarie University Hospital — Macquarie Park, New South Wales, Australia (enrolling)
- Scientia Clinical Research — Randwick, New South Wales, Australia (enrolling)
- Southern Oncology Clinical Research Unit — Bedford Park, South Australia, Australia (enrolling)
- Peninsula and South Eastern Haematology and Oncology Group (PSEHOG) — Frankston, Victoria, Australia (enrolling)
- Cabrini Hospital — Malvern, Victoria, Australia (enrolling)
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (enrolling)
- Linear Clinical Research — Nedlands, Western Australia, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.